Magnetic resonance imaging and spectroscopy assessment of lower extremity skeletal muscles in boys with duchenne muscular dystrophy: A multicenter cross sectional study

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Forbes, Sean C ^a   Willcocks, Rebecca J ^a   Triplett, William T ^a   Rooney, William D ^b   Lott, Donovan J ^a   Wang, Dah Jyuu ^c   Pollaro, Jim ^b   Senesac, Claudia R ^a   Daniels, Michael J ^d   Finkel, Richard S ^c,e   Russman, Barry S ^b   Byrne, Barry J ^a   Finanger, Erika L ^b   Tennekoon, Gihan I ^c   Walter, Glenn A ^a   Sweeney, H Lee ^f   Vandenborne, Krista ^a  

^a UNIVERSITY OF FLORIDA   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^d UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^e NEMOURS CHILDREN S HOSPITAL   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIPID;

ADOLESCENT; AGE DISTRIBUTION; ARTICLE; BICEPS FEMORIS MUSCLE; BODY MASS; CHILD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DESCRIPTIVE RESEARCH; DIAGNOSTIC TEST ACCURACY STUDY; DIFFUSION WEIGHTED IMAGING; DUCHENNE MUSCULAR DYSTROPHY; FLEXOR DIGITORUM LONGUS MUSCLE; HUMAN; LEG MUSCLE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE INJURY; MYOSITIS; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRESCHOOL CHILD; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY; SKELETAL MUSCLE; SOLEUS MUSCLE; VASTUS LATERALIS MUSCLE; CASE CONTROL STUDY; CLINICAL TRIAL; COHORT ANALYSIS; DISEASE COURSE; LEG; LIPID METABOLISM; METABOLISM;

ADOLESCENT; AGE DISTRIBUTION; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; HUMANS; LEG; LIPID METABOLISM; MAGNETIC RESONANCE IMAGING; MALE; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, DUCHENNE;

EID: 84908397254     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0106435     Document Type: Article

References (43)

1. Hoffman EP, Brown RH, Kunkel LM (1987) Dystrophin: The protein product of the Duchenne muscular dystrophy locus. Cell 51: 919-928.
2. Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, et al. (2010) Diagnosis and management of Duchenne muscular dystrophy, part 1: Diagnosis, and pharmacological and psychosocial management. Lancet Neurol 9: 77-93.
3. Daack-Hirsch S, Holtzer C, Cunniff C (2013) Parental perspectives on the diagnostic process for Duchenne and Becker muscular dystrophy. Am J Med Genet A 161: 687-695.
4. Holtzer C, Meaney FJ, Andrews J, Ciafaloni E, Fox DJ, et al. (2011) Disparities in the diagnostic process of Duchenne and Becker muscular dystrophy. Genet Med 13: 942-947.
5. Harper SQ, Hauser MA, DelloRusso C, Duan D, Crawford RW, et al. (2002) Modular flexibility of dystrophin: Implications for gene therapy of Duchenne muscular dystrophy. Nat Med 8: 253-261.
6. Kinali M, Arechavala-Gomeza V, Feng L, Cirak S, Hunt D, et al. (2009) Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: A single-blind, placebo-controlled, dose-escalation, proof-of-concept study. Lancet Neurol 8: 918-928.
7. Welch EM, Barton ER, Zhuo J, Tomizawa Y, Friesen WJ, et al. (2007) PTC124 targets genetic disorders caused by nonsense mutations. Nature 447: 87-91.
8. Connolly AM, Florence JM, Cradock MM, Malkus EC, Schierbecker JR, et al. (2013) Motor and cognitive assessment of infants and young boys with Duchenne Muscular Dystrophy: Results from the Muscular Dystrophy Association DMD Clinical Research Network. Neuromuscul Disord 23: 529-539.
9. Hoffman EP, Connor EM (2013) Orphan drug development in muscular dystrophy: Update on two large clinical trials of dystrophin rescue therapies. Discov Med 16: 233-239.
10. Henricson E, Abresch R, Han JJ, Nicorici A, Keller EG, et al. (2012) Percent-Predicted 6-Minute Walk Distance in Duchenne Muscular Dystrophy to Account for Maturational Influences. PLoS Curr.
11. Mazzone E, Martinelli D, Berardinelli A, Messina S, D'Amico A, et al. (2010) North Star Ambulatory Assessment, 6-minute walk test and timed items in ambulant boys with Duchenne muscular dystrophy. Neuromuscul Disord 20: 712-716.
12. Mazzone ES, Messina S, Vasco G, Main M, Eagle M, et al. (2009) Reliability of the North Star Ambulatory Assessment in a multicentric setting. Neuromuscul Disord 19: 458-461.
13. Mayhew AG, Cano SJ, Scott E, Eagle M, Bushby K, et al. (2013) Detecting meaningful change using the North Star Ambulatory Assessment in Duchenne muscular dystrophy. Dev Med Child Neurol 55: 1046-1052.
14. Azzabou N, Loureiro de Sousa P, Caldas E, Carlier PG (In press) Validation of a generic approach to muscle water T2 determination at 3T in fat-infiltrated skeletal muscle. J Magn Reson Imaging.
15. Friedman SD, Poliachik SL, Carter GT, Budech CB, Bird TD, et al. (2012) The magnetic resonance imaging spectrum of facioscapulohumeral muscular dystrophy. Muscle Nerve 45: 500-506.
16. Arpan I, Forbes SC, Lott DJ, Senesac CR, Daniels MJ, et al. (2012) T2 mapping provides multiple approaches for the characterization of muscle involvement in neuromuscular diseases: A cross-sectional study of lower leg muscles in 5-15-year-old boys with Duchenne muscular dystrophy. NMR in Biomed 26: 320-328.
17. Wren TAL, Bluml S, Tseng-Ong L, Gilsanz V (2008) Three-Point Technique of Fat Quantification of Muscle Tissue as a Marker of Disease Progression in Duchenne Muscular Dystrophy: Preliminary Study. Am J Roentgenol 190: W8-12.
18. Wokke BH, van den Bergen JC, Versluis MJ, Niks EH, Milles J, et al. (2014) Quantitative MRI and strength measurements in the assessment of muscle quality in Duchenne muscular dystrophy. Neuromuscul Disord 24: 409-416.
19. Torriani M, Townsend E, Thomas B, Bredella M, Ghomi R, et al. (2012) Lower leg muscle involvement in Duchenne muscular dystrophy: An MR imaging and spectroscopy study. Skeletal Radiol 41: 437-445.
20. Lott DJ, Forbes SC, Mathur S, Germain SA, Senesac CR, et al. (2014) Assessment of Intramuscular Lipid and Metabolites of the Lower Leg using Magnetic Resonance Spectroscopy in boys with Duchenne muscular dystrophy. Neuromuscul Disord 24: 574-582.
21. Forbes SC, Walter GA, Rooney WD, Wang D-J, DeVos S, et al. (2013) Skeletal Muscles of Ambulant Children with Duchenne Muscular Dystrophy: Validation of Multicenter Study of Evaluation with MR Imaging and MR Spectroscopy. Radiology 269: 198-207.
22. Triplett WT, Baligand C, Forbes SC, Willcocks RJ, Lott DJ, et al. (2014) Chemical shift-based MRI to measure fat fractions in dystrophic skeletal muscle. Magn Reson Med 72: 8-19.
23. Mathur S, Vohra RS, Germain SA, Forbes S, Bryant ND, et al. (2011) Changes in muscle T2 and tissue damage after downhill running in mdx Mice. Muscle Nerve 43: 878-886.
24. Arpan I, Willcocks RJ, Forbes SC, Finkel RS, Lott DJ, et al. (In press) Examination of Effects of Corticosteroids on Skeletal Muscles of Boys with DMD using MRI and MRS. Neurology.
25. Frahm J BH, Gyngell ML, Merboldt KD, Hänicke W, Sauter R. (1989) Localized high-resolution proton NMR spectroscopy using stimulated echoes: Initial applications to human brain in vivo. Magn Reson Med 9: 79-93.
26. Bruhn H FJ, Gyngell ML, Merboldt KD, Hänicke W, Sauter R. (1991) Localized proton NMR spectroscopy using stimulated echoes: Applications to human skeletal muscle in vivo. Magn Reson Med 17: 82-94.
27. Maier CF, Tan SG, Hariharan H, Potter HG (2003) T2 quantitation of articular cartilage at 1.5 T. J Magn Reson Imaging 17: 358-364.
28. Gold GE, Han E, Stainsby J, Wright G, Brittain J, et al. (2004 ) Musculoskeletal MRI at 3.0 T: Relaxation Times and Image Contrast. AJR Am J Roentgenol 183 343-351.
29. Krssak M, Roden M, Mlynarik V, Meyerspeer M, Moser E (2004) 1H NMR relaxation times of skeletal muscle metabolites at 3 T. Magnetic Resonance Materials in Physics, Biology and Medicine 16: 155-159.
30. Elliott MA, Walter GA, Swift A, Vandenborne K, Schotland JC, et al. (1999) Spectral quantitation by principal component analysis using complex singular value decomposition. Magn Reson Imaging 41: 450-455.
31. Forbes SC, Lott DJ, Finkel RS, Senesac C, Byrne BJ, et al. (2012) MRI/MRS evaluation of a female carrier of Duchenne muscular dystrophy. Neuromuscul Disord 22, Supplement 2: S111-S121.
32. Petrof BJ (2006) Molecular pathophysiology of myofiber injury in deficiencies of the dystrophin-glycoprotein complex. Am J Phys Med Rehabil 81: S162-174.
33. Kobayashi YM, Rader EP, Crawford RW, Iyengar NK, Thedens DR, et al. (2008) Sarcolemma-localized nNOS is required to maintain activity after mild exercise. Nature 27: 511-515.
34. Weber MA, Nagel AM, Wolf MB, Jurkat-Rott K, Kauczor HU, et al. (2012) Permanent muscular sodium overload and persistent muscle edema in Duchenne muscular dystrophy: A possible contributor of progressive muscle degeneration. J Neurol 259: 2385-2392.
35. Frisullo G, Frusciante R, Nociti V, Tasca G, Renna R, et al. (2011) CD8+ T Cells in Facioscapulohumeral Muscular Dystrophy Patients with Inflammatory Features at Muscle MRI. J Clin Immunol 31: 155-166.
36. Foley JM, Yayaraman RC, Prior BM, Pivarnik JM, Meyer RA (1999) MR measurements of muscle damage and adaptation after eccentric exercise. J Appl Physiol 87: 2311-2318.
37. Rooney WD, Forbes SC, Triplett W, Wang D-J, Pollaro J, et al. (2013) Soleus Muscle Water T2 Values in Duchenne Muscular Dystrophy: Associations with Age and Corticosteroid Treatment Proc Intl Soc Mag Reson Med 21: 0689.
38. Loganathan R, Bilgen M, Al-Hafez B, Smirnova IR (2005) Characterization of alterations in diabetic myocardial tissue using high resolution MRI. Int J Cardiovasc Imaging 22: 81-90.
39. Marden FA, Connolly AM, Siegel MJ, Rubin DA (2005) Compositional analysis of muscle in boys with Duchenne muscular dystrophy using MR imaging. Skeletal Radiol 34: 140-148.
40. Friedman SD, Poliachik SL, Otto RK, Carter GT, Budech CB, et al. (2014) Longitudinal Features of Stir Bright Signal in FSHD. Muscle Nerve 49: 257-260.
41. Gloor M, Fasler S, Fischmann A, Haas T, Bieri O, et al. (2011) Quantification of fat infiltration in oculopharyngeal muscular dystrophy: Comparison of three MR imaging methods. J Magn Reson Imaging 33: 203-210.
42. Carlier PG (2014) Global T2 versus water T2 in NMR imaging of fatty infiltrated muscles: Different methodology, different information and different implications. Neuromuscul Disord 24: 390-392.
43. Willis TA, Hollingsworth KG, Coombs A, Sveen M-L, Andersen Sr, et al. (2013) Quantitative Muscle MRI as an Assessment Tool for Monitoring Disease Progression in LGMD2I: A Multicentre Longitudinal Study. PLoS One 8: E70993.